Table 3.
Adverse events considered to be associated with study drug administration
| Adverse event | Severity | Number of affected subjects |
|---|---|---|
| Group A | ||
| Abdominal colic | Mild | 1 |
| Abdominal discomfort | Moderate | 1 |
| Abdominal distension | Moderate | 2 |
| Abdominal distension | Mild | 1 |
| Abdominal disturbance | Moderate | 1 |
| Feeling of bloating | Moderate | 1 |
| Flatulence | Moderate | 1 |
| Increased appetite | Mild | 1 |
| Nausea | Moderate | 1 |
| Nausea | Mild | 3 |
| Group B | ||
| Abdominal discomfort | Mild | 1 |
| Abdominal distension | Moderate | 1 |
| Abdominal distension | Mild | 1 |
| Constipation | Moderate | 1 |
| Constipation | Mild | 1 |
| Elevated uric acid | Mild | 2 |
| Epigastralgia | Mild | 2 |
| Epigastralgia | Moderate | 1 |
| Flatulence | Mild | 1 |
| Nausea | Moderate | 1 |
| Nausea | Mild | 1 |
Note: Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.